Program
conestat alfa
Also written as “Ruconest”, “Recombinant Human C1 Inhibitor” and “rhC1INH”.
Its studies are mostly in Angioedemas, Hereditary · COVID-19 · Fatigue Syndrome, Chronic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharming Group | 60 open or running | phase 3since Sep 20, 2005 | Sep 20, 2005 | none ahead |
| IMMUNOe Research Centers | 21 open or running | phase 4since Nov 6, 2026 | Jan 7, 2021 | Jul 31, 2027phase 4 · NCT07932002 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 20, 2005First study: phase 3 study in Angioedemas, HereditaryNew to Pharming GroupPharming Group · NCT00225147 · 77 enrolled · Netherlands
- Dec 1, 2005Phase 3 study in Angioedemas, HereditaryPharming Group · NCT00262301 · 75 enrolled · Netherlands, Romania
- Feb 25, 2009Phase 2 study in Genetic Diseases, InbornPharming Group · NCT00851409 · 25 enrolled · Netherlands, Romania
- May 19, 2011Phase 2 study in Angioedemas, HereditaryPharming Group · NCT01359969 · 57 enrolled · United States, Czechia, Germany and more
- Sep 16, 2014Phase 2 study in Angioedemas, HereditaryPharming Group · NCT02247739 · 32 enrolled · United States, Canada, Czechia and more
- Aug 26, 2020Phase 2 study in Confirmed Coronavirus DiseasePharming Group · NCT04530136 · 38 enrolled · United States
- Jan 7, 2021IMMUNOe Research Centers's first study: phase 2 study in Fatigue Syndrome, ChronicNew to IMMUNOe Research CentersIMMUNOe Research Centers · NCT04705831 · 40 enrolled · United States
- Nov 6, 2026Phase 4 study in COVID-19IMMUNOe Research Centers · NCT07932002 · 30 planned · United States
Ahead
- Jul 31, 2027Primary completion: phase 4 study in COVID-19IMMUNOe Research Centers · NCT07932002
TargetBeta
“A recombinant form of human complement component 1 esterase inhibitor (C1INH), a serine protease inhibitor normally present in human plasma, that can be used for the treatment of hereditary angioedema (HAE)”NCIt, by rule
“Plasma protease C1 inhibitor exogenous protein”ChEMBL 37, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07932002COVID-19 · United States | 4 | Recruiting | IMMUNOe Research Centers | Jul 31, 2027 | 30 |
| NCT04705831Fatigue Syndrome, Chronic · United States | 2 | Completed | IMMUNOe Research Centers | Mar 30, 2024 | 40 |
| NCT04530136Confirmed Coronavirus Disease · United States | 2 | Completed | Pharming Group | Sep 7, 2021 | 38 |
| NCT02247739Angioedemas, Hereditary · United States, Canada, Czechia and more | 2 | Completed | Pharming Group | May 2016 | 32 |
| NCT01359969Angioedemas, Hereditary · United States, Czechia, Germany and more | 2 | Completed | Pharming Group | Jul 17, 2017 | 57 |
| NCT00851409Genetic Diseases, Inborn · Netherlands, Romania | 2 | Completed | Pharming Group | Mar 2010 | 25 |
| NCT00262301Angioedemas, Hereditary · Netherlands, Romania | 3 | Completed | Pharming Group | Jul 2009 | 75 |
| NCT00225147Angioedemas, Hereditary · Netherlands | 3 | Completed | Pharming Group | Oct 2009 | 77 |
How it is read
Names in the registry
- “Ruconest”, 3 entries
- “Recombinant Human C1 Inhibitor”, 2 entries
- “rhC1INH”, 1 entry
- “Recombinant human C1 inhibitor”, 1 entry
- “recombinant human C1 inhibitor”, 1 entry
Conditions, from the studies’ own filings
- Angioedemas, Hereditary, 5 studies
- COVID-19, 1 study
- Fatigue Syndrome, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.